Literature DB >> 24525055

Overlapping microdeletions involving 15q22.2 narrow the critical region for intellectual disability to NARG2 and RORA.

Toshiyuki Yamamoto1, Maria Antonietta Mencarelli2, Chiara Di Marco2, Mafalda Mucciolo3, Marina Vascotto4, Paolo Balestri4, Marion Gérard5, Michèle Mathieu-Dramard5, Joris Andrieux5, Martijn Breuning6, Mariëtte J V Hoffer6, Claudia A L Ruivenkamp6, Shino Shimada7, Noriko Sangu8, Keiko Shimojima9, Ryoji Umezu10, Hiroshi Kawame11, Mari Matsuo12, Kayoko Saito12, Alessandra Renieri2, Francesca Mari2.   

Abstract

Microdeletions in the 15q22 region have not been well documented. We collected genotype and phenotype data from five patients with microdeletions involving 15q22.2, which were between 0.7 Mb and 6.5 Mb in size; two were of de novo origin and one was of familial origin. Intellectual disability and epilepsy are frequently observed in patients with 15q22.2 deletions. Genotype-phenotype correlation analysis narrowed the critical region for such neurologic symptoms to a genomic region of 654 Kb including the NMDA receptor-regulated 2 gene (NARG2) and the PAR-related orphan receptor A gene (RORA), either of which may be responsible for neurological symptoms commonly observed in patients with deletions in this region. The neighboring regions, including the forkhead box B1 gene (FOXB1), may also be related to the additional neurological features observed in the patients with larger deletions. Crown
Copyright © 2014. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  15q22.2; Epilepsy; Forkhead box B1 (FOXB1); Intellectual disability; Microdeletion; NMDA receptor-regulated 2 (NARG2); RAR-related orphan receptor A (RORA)

Mesh:

Substances:

Year:  2014        PMID: 24525055     DOI: 10.1016/j.ejmg.2014.02.001

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  4 in total

1.  Dual Molecular Effects of Dominant RORA Mutations Cause Two Variants of Syndromic Intellectual Disability with Either Autism or Cerebellar Ataxia.

Authors:  Claire Guissart; Xenia Latypova; Paul Rollier; Tahir N Khan; Hannah Stamberger; Kirsty McWalter; Megan T Cho; Susanne Kjaergaard; Sarah Weckhuysen; Gaetan Lesca; Thomas Besnard; Katrin Õunap; Lynn Schema; Andreas G Chiocchetti; Marie McDonald; Julitta de Bellescize; Marie Vincent; Hilde Van Esch; Shannon Sattler; Irman Forghani; Isabelle Thiffault; Christine M Freitag; Deborah Sara Barbouth; Maxime Cadieux-Dion; Rebecca Willaert; Maria J Guillen Sacoto; Nicole P Safina; Christèle Dubourg; Lauren Grote; Wilfrid Carré; Carol Saunders; Sander Pajusalu; Emily Farrow; Anne Boland; Danielle Hays Karlowicz; Jean-François Deleuze; Monica H Wojcik; Rena Pressman; Bertrand Isidor; Annick Vogels; Wim Van Paesschen; Lihadh Al-Gazali; Aisha Mohamed Al Shamsi; Mireille Claustres; Aurora Pujol; Stephan J Sanders; François Rivier; Nicolas Leboucq; Benjamin Cogné; Souphatta Sasorith; Damien Sanlaville; Kyle Retterer; Sylvie Odent; Nicholas Katsanis; Stéphane Bézieau; Michel Koenig; Erica E Davis; Laurent Pasquier; Sébastien Küry
Journal:  Am J Hum Genet       Date:  2018-04-12       Impact factor: 11.025

2.  Assembly of a comprehensive regulatory network for the mammalian circadian clock: a bioinformatics approach.

Authors:  Robert Lehmann; Liam Childs; Philippe Thomas; Monica Abreu; Luise Fuhr; Hanspeter Herzel; Ulf Leser; Angela Relógio
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

3.  TCF12 microdeletion in a 72-year-old woman with intellectual disability.

Authors:  Juliette Piard; Virginie Rozé; Alain Czorny; Marion Lenoir; Mylène Valduga; Aimée L Fenwick; Andrew O M Wilkie; Lionel Van Maldergem
Journal:  Am J Med Genet A       Date:  2015-04-13       Impact factor: 2.802

4.  MiR-18a-downregulated RORA inhibits the proliferation and tumorigenesis of glioma using the TNF-α-mediated NF-κB signaling pathway.

Authors:  Yang Jiang; Jinpeng Zhou; Junshuang Zhao; Dianqi Hou; Haiying Zhang; Long Li; Dan Zou; Jiangfeng Hu; Ye Zhang; Zhitao Jing
Journal:  EBioMedicine       Date:  2020-02-12       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.